Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.
Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, Choi DS, Lluch A, Liu Y, Rojo F, Wong H, Martínez-Dueñas E, Guerrero-Zotano Á, Shao ZM, Darcourt JG, Mills GB, Dave B, Chang JC. Liu ZB, et al. Among authors: eterovic ak. Breast Cancer Res Treat. 2019 Nov;178(2):251-261. doi: 10.1007/s10549-019-05374-x. Epub 2019 Aug 6. Breast Cancer Res Treat. 2019. PMID: 31388936 Free PMC article.
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
Lluch A, González-Angulo AM, Casadevall D, Eterovic AK, Martínez de Dueñas E, Zheng X, Guerrero-Zotano Á, Liu S, Pérez R, Chen K, Chacón JI, Mills GB, Antolín S, Blancas I, López-Serra P, Carrasco E, Caballero R, Prat A, Rojo F, Gonzalez-Perez A, Meric-Bernstam F, Albanell J. Lluch A, et al. Among authors: eterovic ak. Eur J Cancer. 2019 Oct;120:54-64. doi: 10.1016/j.ejca.2019.07.003. Epub 2019 Sep 4. Eur J Cancer. 2019. PMID: 31491604
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. Evans KW, et al. Among authors: eterovic ak. Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615. Clin Cancer Res. 2017. PMID: 29093017 Free PMC article.
Functional consequence of the MET-T1010I polymorphism in breast cancer.
Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Liu S, et al. Among authors: eterovic ak. Oncotarget. 2015 Feb 20;6(5):2604-14. doi: 10.18632/oncotarget.3094. Oncotarget. 2015. PMID: 25605252 Free PMC article.
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Roszik J, et al. Among authors: eterovic ak. BMC Med. 2016 Oct 25;14(1):168. doi: 10.1186/s12916-016-0705-4. BMC Med. 2016. PMID: 27776519 Free PMC article.
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL Jr, Grimm EA, Lazar AJ, Woodman SE. McKean M, et al. Among authors: eterovic ak. J Invest Dermatol. 2019 Mar;139(3):728-731. doi: 10.1016/j.jid.2018.10.009. Epub 2018 Oct 25. J Invest Dermatol. 2019. PMID: 30798855 Free article. No abstract available.
Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.
Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Oba J, et al. Among authors: eterovic ak. JCO Precis Oncol. 2018;2018:PO.18.00055. doi: 10.1200/PO.18.00055. Epub 2018 Jun 5. JCO Precis Oncol. 2018. PMID: 30094412 Free PMC article. No abstract available.
Extend the benchmarking indel set by manual review using the individual cell line sequencing data from the Sequencing Quality Control 2 (SEQC2) project.
Gong B, Li D, Zhang Y, Kusko R, Lababidi S, Cao Z, Chen M, Chen N, Chen Q, Chen Q, Dai J, Gan Q, Gao Y, Guo M, Hariani G, He Y, Hou W, Jiang H, Kushwaha G, Li JL, Li J, Li Y, Liu LC, Liu R, Liu S, Meriaux E, Mo M, Moore M, Moss TJ, Niu Q, Patel A, Ren L, Saremi NF, Shang E, Shang J, Song P, Sun S, Urban BJ, Wang D, Wang S, Wen Z, Xiong X, Yang J, Yin L, Zhang C, Zhang R, Bhandari A, Cai W, Eterovic AK, Megherbi DB, Shi T, Suo C, Yu Y, Zheng Y, Novoradovskaya N, Sears RL, Shi L, Jones W, Tong W, Xu J. Gong B, et al. Among authors: eterovic ak. Sci Rep. 2024 Mar 25;14(1):7028. doi: 10.1038/s41598-024-57439-7. Sci Rep. 2024. PMID: 38528062 Free PMC article.
47 results